Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 10/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768341 | 0.79 | GRM4 (0.59) | GRM4LRRK2KMT2AEGFR | |
| SCHEMBL3777103 | 0.78 | LRRK2 (0.38) | SYKLRRK2 | |
| SCHEMBL3777119 | 0.77 | GRM4 (0.39) | GRM4LRRK2EGFR | |
| SCHEMBL3771231 | 0.77 | GRM4 (0.56) | GRM4KMT2AEGFR | |
| SCHEMBL3769390 | 0.77 | EGFR (0.54) | GRM4EGFR | |
| SCHEMBL3775816 | 0.77 | EGFR (0.54) | PIM1SYKGRM4EGFR | |
| SCHEMBL13060929 | 0.77 | GRM4 (0.44) | GRM4LRRK2EGFR | |
| SCHEMBL3771920 | 0.77 | GRM4 (0.56) | GRM4KMT2AEGFR | |
| SCHEMBL3774794 | 0.76 | GRM4 (0.50) | GRM4LRRK2KMT2AEGFR | |
| SCHEMBL3773000 | 0.76 | NOTUM (0.42) | PIM1GRM4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | AAK1 4486/4885PIM1 4300/4885SYK 2282/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | AAK1 4508/4885PIM1 4318/4885SYK 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.